sativex (27 mg + 25 mg)/ml aerozol do stosowania w jamie ustnej
jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum + cannabidiolum - aerozol do stosowania w jamie ustnej - (27 mg + 25 mg)/ml
tramofen 37,5 mg + 325 mg tabletki powlekane
vitama s.a. - tramadoli hydrochloridum + paracetamolum - tabletki powlekane - 37,5 mg + 325 mg
tramadol aurovitas 50 mg kapsułki twarde
aurovitas pharma polska sp. z o.o. - tramadoli hydrochloridum - kapsułki twarde - 50 mg
enstilar (50 mcg + 0,5 mg)/g piana na skórę
leo pharma a/s - calcipotriolum + betamethasoni dipropionas - piana na skórę - (50 mcg + 0,5 mg)/g
domark 100 ec
gowan crop protection limited rothamsted research, west common, harpenden, al5 2jq , wielka brytania - tetrakonazol - tetrakonazol - 100 g - fungicyd
ilumetri
almirall s.a - tildrakizumab - Łuszczyca - leki immunosupresyjne, inhibitory interleukiny, - ilumetri jest wskazany do leczenia dorosłych pacjentów z umiarkowaną do ciężkiej prasowania łuszczyca, które są kandydatami do terapii systemowej.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - leki immunosupresyjne - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
aklief 50 mcg/g krem
galderma polska sp. z o.o. - trifarotenum - krem - 50 mcg/g
bimzelx
ucb pharma s.a. - bimekizumab - Łuszczyca - leki immunosupresyjne - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
saphnelo
astrazeneca ab - anifrolumab - liszaj rumieniowaty, układowy - leki immunosupresyjne - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.